Does cognitive impairment in Parkinson's disease result from non-dopaminergic lesions?
- PMID: 2703838
- PMCID: PMC1032506
- DOI: 10.1136/jnnp.52.2.201
Does cognitive impairment in Parkinson's disease result from non-dopaminergic lesions?
Abstract
In order to investigate the neuronal basis of cognitive disorders in Parkinson's disease, the neuropsychological performance of 120 patients with idiopathic Parkinson's disease was analysed in relation to motor symptoms as a function of their response to levodopa. Cognitive impairment was poorly correlated with akinesia and rigidity, symptoms which respond well to levodopa treatment, and was not correlated at all with that part of the patients' motor score that could be improved by the drug. In contrast, strong correlations were found between all neuropsychological test scores and axial symptoms such as gait disorder and dysarthria, which respond little if at all to levodopa treatment. The neuropsychological test scores were also strongly correlated with the motor score of patients estimated when clinical improvement was maximal under levodopa treatment. This score is assumed to represent residual non-dopaminergic motor dysfunctions. The correlations suggest that much of the cognitive impairment in Parkinson's disease results from the dysfunction of non-dopaminergic neuronal systems.
Similar articles
-
[Levodopa and cognitive disorders in Parkinson's disease].Rev Neurol. 2006 Jul 16-31;43(2):95-100. Rev Neurol. 2006. PMID: 16838257 Review. Spanish.
-
Dopaminergic induced changes in cognitive and motor processing in Parkinson's disease: an electrophysiological investigation.J Neurol Neurosurg Psychiatry. 1991 Jul;54(7):603-9. doi: 10.1136/jnnp.54.7.603. J Neurol Neurosurg Psychiatry. 1991. PMID: 1895125 Free PMC article.
-
Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease. A follow-up study of untreated patients.Brain. 1992 Dec;115 ( Pt 6):1701-25. doi: 10.1093/brain/115.6.1701. Brain. 1992. PMID: 1486457 Clinical Trial.
-
Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: a two-year follow-up study of previously untreated patients.Mov Disord. 2000 Jul;15(4):613-26. doi: 10.1002/1531-8257(200007)15:4<613::aid-mds1005>3.0.co;2-f. Mov Disord. 2000. PMID: 10928571 Clinical Trial.
-
Dopamine and the regulation of cognition and attention.Prog Neurobiol. 2002 May;67(1):53-83. doi: 10.1016/s0301-0082(02)00011-4. Prog Neurobiol. 2002. PMID: 12126656 Review.
Cited by
-
Mild cognitive impairment in Parkinson's disease.J Neural Transm (Vienna). 2013 Apr;120(4):517-21. doi: 10.1007/s00702-013-1006-0. Epub 2013 Mar 19. J Neural Transm (Vienna). 2013. PMID: 23508527 Review.
-
Toxin-Induced Experimental Models of Learning and Memory Impairment.Int J Mol Sci. 2016 Sep 1;17(9):1447. doi: 10.3390/ijms17091447. Int J Mol Sci. 2016. PMID: 27598124 Free PMC article. Review.
-
Neuropsychological profile linked to low dopamine: in Alzheimer's disease, major depression, and Parkinson's disease.J Neurol Neurosurg Psychiatry. 1990 Oct;53(10):915-7. doi: 10.1136/jnnp.53.10.915. J Neurol Neurosurg Psychiatry. 1990. PMID: 2266376 Free PMC article.
-
Role of dopamine in learning and memory: implications for the treatment of cognitive dysfunction in patients with Parkinson's disease.Drugs Aging. 2000 May;16(5):365-79. doi: 10.2165/00002512-200016050-00006. Drugs Aging. 2000. PMID: 10917074 Review.
-
Apathy in Parkinson's disease: an electrophysiological study.Neurol Res Int. 2014;2014:290513. doi: 10.1155/2014/290513. Epub 2014 Apr 7. Neurol Res Int. 2014. PMID: 24804097 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical